Pennsylvania Risperdal Breast Verdict Stands, Cut To $680,000; Janssen To Appeal

(April 6, 2016, 11:54 AM EDT) -- PHILADELPHIA — Janssen Pharmaceuticals Inc. and Johnson & Johnson on April 1 said they will appeal a Risperdal gynecomastia verdict, even after the court on March 10 reduced the original $1.75 million award to a statutory maximum of $680,000 (Nicholas Murray v. Janssen Pharmaceuticals, Inc., et al., No. 130401990, Pa. Comm. Pls., Philadelphia Co.).

On Nov. 9, a jury in the Philadelphia Common Pleas Court awarded Nicholas Murray $1.75 million. Murray alleged that his use of the atypical antipsychotic drug Risperdal from as young as 4...
To view the full article, register now.